Related Experiment Videos
Pharmacogenetics and adverse drug reactions
1Division of Pharmacology/Neurobiology, Biozentrum of the University of Basel, Switzerland. Urs-A.Meyer@unibas.ch
Lancet (London, England)
|November 23, 2000
Summary
Genetic variations in drug-related genes influence adverse drug reactions and treatment efficacy. Pharmacogenomic analysis of these genetic polymorphisms can optimize future drug therapies.
Area of Science:
- Pharmacogenomics
- Genetics
- Drug Metabolism
Background:
- Genetic polymorphisms in genes encoding drug-metabolising enzymes, transporters, receptors, and ion channels can influence individual drug responses.
- Mutant alleles, particularly in drug-metabolising enzyme genes, are significant risk factors for adverse drug reactions.
- These genetic variations lead to distinct metabolic phenotypes, such as "poor metabolisers" and "ultrarapid metabolisers," affecting numerous drugs.
Purpose of the Study:
- To highlight the impact of genetic polymorphisms on drug response.
- To emphasize the role of pharmacogenomic techniques in analyzing these genetic factors.
- To discuss the potential of genotyping tests in optimizing drug therapy.
Main Methods:
- Analysis of genetic polymorphisms in genes related to drug action.
- Identification of mutant alleles and their association with adverse drug reactions.
- Phenotyping of individuals based on drug metabolism rates (e.g., poor vs. ultrarapid metabolisers).
Main Results:
- Genetic polymorphisms significantly alter an individual's risk of adverse drug reactions.
- These variations can also modify the efficacy of drug treatments.
- Specific phenotypes like poor and ultrarapid metabolism are common in the population.
Conclusions:
- Genetic variations are crucial determinants of drug response and safety.
- Pharmacogenomic approaches offer efficient methods for assessing these genetic risks.
- Future applications of genotyping tests hold promise for personalized and optimized drug therapy.